Two Sigma Advisers
JAZZ icon

Two Sigma Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Two Sigma Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,000
Closed -$294K – 2499
2014
Q2 		$294K Buy
+2,000
New +$277K ﹤0.01% 2016

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Two Sigma Advisers's JAZZ Position: Q2 2025 in Review

Two Sigma Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 98,200 shares — an estimated $12.2M sold.

Two Sigma Advisers first reported a position in JAZZ in Q2 2013 and held it in 41 quarters. The position peaked at $76M in Q1 2019. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Two Sigma Advisers reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 98,200 Jazz Pharmaceuticals shares in Q2 2025, an estimated $12.2M.
  • Two Sigma Advisers first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 41 quarters.
  • Two Sigma Advisers's Jazz Pharmaceuticals position peaked at $76M in Q1 2019.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.